{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreid4drpquzh7cmg5lkp7fj7tw3lmzi7usk7ufbrifqlfnelfna5pvi",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mpp4krzz3iw2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreigeyxo4iaxxmfbqewqrhhhbcqonxqklpezhxldjykaiv4bpn65nma"
    },
    "mimeType": "image/jpeg",
    "size": 163553
  },
  "path": "/news/2026-07-bofanglutide-linked-meaningful-reductions-hba1c.html",
  "publishedAt": "2026-07-02T17:20:06.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "For adults with type 2 diabetes mellitus (T2DM), bofanglutide, a glucagon-like peptide-1 receptor agonist, is associated with more meaningful reductions in hemoglobin A1C (HbA1c) levels than semaglutide, according to a study published online June 30 in the Annals of Internal Medicine.",
  "title": "Bofanglutide linked to meaningful reductions in HbA1c in adults with T2DM"
}